又破3万亿，寒武纪股价盘中超越茅台

Market Overview - The A-share market experienced a decline in the afternoon, with the Shanghai Composite Index falling by 1.76%, the Shenzhen Component Index down by 1.43%, and the ChiNext Index decreasing by 0.69% [1] - The total trading volume exceeded 3.19 trillion yuan, marking the third instance in A-share history to surpass 3 trillion yuan in a single day [1] Sector Performance - Rare earth permanent magnet stocks showed strong performance, with Beikong Technology hitting the daily limit and Northern Rare Earth rising over 8%, briefly reaching the top of the Tonghuashun hot stock list [4][7] - The computing power leasing sector also saw gains, with Hongjing Technology surging over 19% at one point, closing up 8.71% [4] - In contrast, sectors such as real estate, liquor, beauty care, and innovative pharmaceuticals faced significant declines [4] Notable Stocks - Cambrian-U saw a rise of over 10% during the day, briefly surpassing Kweichow Moutai in stock price, and closing up 3.24% at 1372.1 yuan per share [4] - Kweichow Moutai closed down 2.27% at 1448 yuan per share [4] - Cambrian has increased over 93% since August [4] Rare Earth Sector Drivers - Key factors driving the rare earth sector include: - Policy support from the Ministry of Industry and Information Technology, which recently issued guidelines for rare earth mining and separation [10] - Significant revenue growth reported by Northern Rare Earth, with a 45.24% increase in revenue to 18.866 billion yuan and a staggering 1951.52% increase in net profit to 931 million yuan [10] - Rising prices of rare earth minerals and magnetic materials, contributing to a tight supply-demand balance [10] - Positive outlook for the entire rare earth permanent magnet industry chain, with strong orders from both upstream and downstream players [10] - Technological advancements by leading companies, enhancing competitiveness while reducing costs [10] Innovative Pharmaceuticals Sector - The innovative pharmaceuticals sector faced a downturn, with stocks like Yuekang Pharmaceutical dropping over 16%, and others like Hotgen Biotech and Guangsheng Tang falling more than 10% [11] - Analysts suggest that as the interim report season concludes, market focus will shift towards new directions, with continued optimism for innovative pharmaceuticals and overseas expansion [12]